Hyaluronidase Power Injection Market Players:
- Argenx SE
- Company Overview
- Business Planning
- Main Product Offerings
- Financial Execution
- Main Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- PrimaPharma, Inc.,
- Halozyme, Inc.
- Bausch & Lomb Incorporated
- The Cooper Companies Inc.,
- Sun Pharmaceutical Industries Ltd.
- STEMCELL Technologies Inc.
- Shijiazhuang Yiang Technology Co., Ltd.
- Calzyme
- Dermax Medical Technology (Hebei) Co., Ltd.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of hyaluronidase power injection is estimated at USD 1.16 billion.
The global hyaluronidase power injection market size was over USD 1.07 billion in 2025 and is anticipated to witness a CAGR of around 9.3%, crossing USD 2.6 billion revenue by 2035.
By 2035, North America in the hyaluronidase power injection market is expected to command a 30% share owing to the rising volume of experimental procedures and strong presence of key manufacturers.
Key players in the market include PrimaPharma, Inc., Halozyme, Inc., Bausch & Lomb Incorporated, The Cooper Companies Inc., Sun Pharmaceutical Industries Ltd., STEMCELL Technologies Inc., Shijiazhuang Yiang Technology Co., Ltd., Calzyme, Dermax Medical Technology (Hebei) Co., Ltd., Takeda Pharmaceuticals Co Limited, Janssen Global Services, LLC, Astellas Pharma Inc., Seagen Inc.
